Cancer research has traditionally depended heavily on controlled clinical trials, but the treatment experience that occurs outside those trials is generating an increasingly valuable source of evidence. Patients receive different therapies, move between care settings, respond differently to treatment, and experience outcomes over long periods that may not always be fully captured within traditional study designs. The Real World Evidence Solutions For Oncology Market is growing around the ability to transform these everyday healthcare experiences into structured evidence that can influence drug development, treatment evaluation, regulatory decisions, reimbursement, and precision oncology.

The global market was valued at USD 703.2 million in 2025 and is projected to reach USD 1,437.1 million by 2033, expanding at a 9.5% CAGR from 2026 to 2033. North America held the largest share at 43.1% in 2025, while Asia Pacific is projected to be the fastest-growing regional market. Services represented 57.8% of revenue, breast cancer accounted for 25.1% by cancer type, and drug development and clinical research represented 26.0% by application in 2025.

Key Highlights

• 2025 market size: USD 703.2 million
• 2033 projected size: USD 1,437.1 million
• CAGR: 9.5% from 2026 to 2033
• Leading region: North America with 43.1% share in 2025
• Leading component: Services with 57.8% share
• Leading cancer type: Breast cancer with 25.1% share
• Leading application: Drug development & clinical research with 26.0% share

The Evidence Is Already Being Generated Every Day

A cancer patient's healthcare journey generates enormous amounts of information. Electronic health records contain diagnoses and treatment histories, cancer registries capture disease characteristics and outcomes, claims databases reveal treatment utilization and healthcare costs, while genomic, biomarker, and patient-generated data add further clinical context. The challenge is no longer simply collecting information, but transforming fragmented data into reliable evidence.

Download a free sample report or claim your copy of this full market intelligence report

Patient encounter → clinical record → data integration → analysis → evidence → healthcare decision

This transformation is giving real-world evidence (RWE) a broader role in oncology. Instead of relying only on controlled research environments, researchers and healthcare companies can examine how therapies perform across diverse patient populations and routine care settings. The growing use of EHRs, cancer registries, genomic databases, AI-driven analytics, and precision medicine is supporting the expansion of the market.

Oncology Needs Evidence That Reflects Real Patients

Cancer treatment is rarely uniform. Patients with the same broad diagnosis can have different biomarkers, treatment histories, comorbidities, responses, and care pathways. RWE can help researchers understand treatment performance across patient groups, treatment patterns in routine practice, long-term outcomes, and results following broader commercialization.

This makes RWE particularly relevant to precision oncology.

Clinical characteristics + genomic information + treatment history + observed outcomes → more individualized evidence

As oncology becomes more personalized, demand is increasing for richer, multimodal datasets capable of explaining differences between patient populations.

Drug Development Remains a Major Application

Drug development and clinical research represented 26.0% of market revenue in 2025, making it the largest application segment. RWE can contribute to study design, patient identification, treatment evaluation, evidence generation, and post-trial analysis. The development pathway is increasingly connected through research questions, patient population identification, trial strategy, real-world comparison, and evidence generation. RWE does not replace clinical trials; instead, it complements them by helping researchers understand treatment patterns and outcomes in routine care, including populations that may be underrepresented in conventional trials.

Services Capture a Significant Share

The services segment accounted for 57.8% of market revenue in 2025 and is expected to maintain strong growth. Oncology evidence generation requires specialized capabilities to clean, structure, analyze, validate, interpret, and communicate complex datasets. Services can include study design, analytics, health economics and outcomes research, regulatory support, post-market evidence generation, and consulting. This reflects a broader market shift from simply owning data toward extracting decision-ready insight from data.

Looking for more in-depth data focusing on specific segments or regions? Get this report customized with inclusion of custom data sets to suit your exact business needs.

AI Is Accelerating Evidence Generation

Oncology datasets include clinical notes, pathology information, imaging, genomic data, laboratory results, and treatment records. AI, machine learning, and natural language processing can help analyze these sources at scale, supporting patient stratification, cohort development, outcome analysis, and signal identification.

Large oncology datasets → AI processing → hidden patterns → clinically relevant insight

The integration of AI, NLP, machine learning, and multi-omics analytics is therefore becoming an important part of oncology RWE solutions.

Breast Cancer Leads While Lung Cancer Gains Momentum

Breast cancer accounted for 25.1% of market revenue by cancer type in 2025, supported by its substantial disease burden and extensive research activity. Lung cancer, meanwhile, is expected to be the fastest-growing cancer-type segment, driven by increasing disease burden, precision oncology, and growing availability of clinical and genomic information.

RWE Is Expanding Into Reimbursement

The role of RWE increasingly extends beyond research. Value-based healthcare is encouraging payers and healthcare organizations to assess whether oncology treatments deliver measurable value in real-world settings.

Therapy launch → real-world use → outcomes measurement → economic assessment → coverage decision

Market access and reimbursement is expected to be the fastest-growing application area as payers seek evidence related to comparative effectiveness, long-term safety, healthcare utilization, and treatment value.

Privacy Remains a Critical Consideration

Greater access to oncology data also increases privacy responsibilities. EHRs, genomic information, treatment histories, and patient-generated data require careful attention to security, consent, anonymization, interoperability, and regional regulations. Data quality, transparency, methodological rigor, and patient protection are becoming increasingly important for building confidence in RWE.

Regional Outlook

North America currently leads the market due to mature healthcare data infrastructure, high EHR adoption, a strong oncology research ecosystem, and increasing regulatory acceptance of RWE.

Asia Pacific is expected to record an 11.3% CAGR from 2026 to 2033, supported by rising cancer prevalence, healthcare digitalization, precision oncology initiatives, and developing oncology datasets. Japan, China, and India are contributing to the region's evolving evidence infrastructure, while Europe is strengthening its RWE environment through greater coordination among healthcare data systems, regulators, and health technology assessment organizations.

Key Companies

The competitive landscape includes IQVIA, Merative, PPD, Inc. (a subsidiary of Thermo Fisher Scientific Inc.), Parexel International Corporation, ICON Plc, Oracle, Syneos Health

Explore the full list of profiled companies operating in this market with recent strategic initiatives

About us:

Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.